两星期重复剂量口服嗜酸乳杆菌 J9 在小鼠模型中的毒性研究。
Two-weeks repeated-dose oral toxicity study of Pediococcus acidilactici J9 in a mice model.
机构信息
Department of Neurology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.
Department of Veterinary Internal Medicine and Geriatrics, College of Veterinary Medicine, Kangwon National University, Gangwon-do, South Korea.
出版信息
BMC Microbiol. 2020 Dec 9;20(1):372. doi: 10.1186/s12866-020-02055-4.
BACKGROUND
Helicobacter pylori (H. pylori) is an important pathogen that causes chronic gastritis and peptic ulcer, and is related to the development of gastric carcinoma. Several chemicals, including antibiotics, have been used to eradicate H.pylori. However, more studies are yet requred to accomplish a sufficient therapy. Pediococcus acidilactici (P. acidilactici) J9 were studied for inhibition of binding of H.pylori binding to human gastric cell lines. This study was performed in order to investigate the repeated-dose toxicity of P. acidilactici J9 in male and female mice.
RESULTS
C57BL/6 male and female Mus musculus were divided into four groups (n = 10 in each group). P. acidilactici J9 was administered daily by oral injection of vehicle control at dosage levels to a low-dose group (500 mg/kg/day), middle-dose group (1000 mg/kg/day), and high-dose group (2000 mg/kg/day) for 2 weeks. After 14 days of exposure, the blood biochemistry and hematology were investigated, along with a histopathology exam. There were no bacterial-related deaths or abnormal clinical signs in either gender of mouse. The data was observed during the period in terms of body weight, food intake, and water consumption. Also, no alterations in organ weights upon administration of P. acidilactici J9 alone were observed. The adhesion and growth of H. pylori were inhibited by a 24 h treatment of H. pylori and P. acidilactici J9 on adenocarcinoma gastric (AGS) cells, which are gastric cancer cells. Compared to the control group (AGS cell and H. pylori), the number of H. pylori analyzed by FACS significantly (p < 0.01) decreased after incubation of AGS cell with P. acidilactici J9 for 24 h.
CONCLUSIONS
These results suggest that the oral application of P. acidilactici J9, up to a dosage level of 2000 mg/kg/day, causes no adverse effects in both male and female mice. P. acidilactici J9 inhibits the adhesion of H.pylori to AGS cancer cells. When used as probiotics, P. acidilactici J9 may help decrease the occurrence of gastritis and reduce the risk of H.pylori infection with promising safety issues.
背景
幽门螺杆菌（H. pylori）是一种重要的病原体，可导致慢性胃炎和消化性溃疡，并与胃癌的发展有关。几种化学物质，包括抗生素，已被用于根除 H.pylori。然而，还需要更多的研究来实现足够的治疗。已研究了植物乳杆菌（P. acidilactici）J9 抑制 H.pylori 与人胃细胞系结合的能力。进行这项研究是为了调查 P. acidilactici J9 在雄性和雌性小鼠中的重复剂量毒性。
结果
C57BL/6 雄性和雌性 Mus musculus 被分为四组（每组 10 只）。通过口服注射 vehicle 对照，每日给予 P. acidilactici J9，低剂量组（500mg/kg/天）、中剂量组（1000mg/kg/天）和高剂量组（2000mg/kg/天），连续 2 周。暴露 14 天后，检查血液生化和血液学，并进行组织病理学检查。在雄性和雌性小鼠中均未观察到与细菌相关的死亡或异常临床症状。在给药期间观察了体重、食物摄入和水消耗等数据。单独给予 P. acidilactici J9 时，也未观察到器官重量发生变化。用 H. pylori 和 P. acidilactici J9 处理腺癌胃（AGS）细胞 24 小时可抑制 H. pylori 的粘附和生长，AGS 细胞是胃癌细胞。与对照组（AGS 细胞和 H. pylori）相比，用 P. acidilactici J9 孵育 24 小时后，通过 FACS 分析的 H. pylori 数量显著（p<0.01）减少。
结论
这些结果表明，口服应用 P. acidilactici J9，剂量高达 2000mg/kg/天，在雄性和雌性小鼠中均无不良影响。P. acidilactici J9 抑制 H.pylori 与 AGS 癌细胞的粘附。当用作益生菌时，P. acidilactici J9 可能有助于减少胃炎的发生，并降低 H.pylori 感染的风险，具有良好的安全性。
Zotero 插件